Global Hypogammaglobulinemia Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1.45 Billion |
 Market Size (Forecast Year) |
USD 2.50 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球低丙种球蛋白血症药物市场，按类型（皮质类固醇、化疗、抗癫痫药物等）、治疗（抗生素、免疫球蛋白替代疗法等）、最终用户（医院、专科诊所、其他）、分销渠道（医院药房、零售药房、其他）划分 - 行业趋势和预测到 2030 年。
低丙种球蛋白血症药物市场分析及规模
预计低丙种球蛋白血症药物市场在预测期内将出现巨大增长。由于久坐的生活方式、肥胖、大量饮酒和缺乏体育锻炼，儿童中丙种球蛋白血症患病率不断上升，这是低丙种球蛋白血症药物市场的主要驱动因素。发展中经济体和不断增长的医疗支出为低丙种球蛋白血症药物市场提供了最大的机会。此外，主要参与者正更加专注于开发具有成本效益的疗法并在全球范围内大规模生产。
Data Bridge Market Research 分析了 2023-2030 年预测期内低丙种球蛋白血症药物市场的增长率。在上述预测期内，低丙种球蛋白血症药物市场的预期复合年增长率约为 7%。2022 年市场价值为 14.5 亿美元，到 2030 年将增长至 25 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
低丙种球蛋白血症药物市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（皮质类固醇、化疗、抗癫痫药物等）、治疗（抗生素、免疫球蛋白替代疗法等）、最终用户（医院、专科诊所等）、分销渠道（医院药房、零售药房等） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
Biotest AG (Germany), Octapharma Brasil Ltda (Switzerland), Grifols, S.A (Spain), CSL (U.S.), Kedrion S.p.A (Italy), LFB (France), Takeda Pharmaceutical Company Limited (Japan), ADMA Biologics, Inc. (U.S.), Bayer AG (Germany), Option Care Health Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
Hypogammaglobulinemia is a type of immune disorder that is characterized by insufficient production of gamma globulins in human blood. It causes decline in the antibody count and therefore affects the immune system. Antibodies play a major role in fighting against any foreign and invade particles without antibodies. The incidence rate of hypogammaglobulinemia can be observed in both female and males and cause severe complications. The most common symptoms include bronchitis, skin infection, sinus infections, ear infections, malabsorption, and respiratory infections.
Global Hypogammaglobulinemia Drugs Market Dynamics
Drivers
- High Prevalence of Immune Deficiencies
As per the records of the W.H.O, there are over 50 different Primary Immune Deficiencies (PIDs) such as specific antibody deficiency and X-lined hypo-gamma-globulinemia. PIDs include 176 several types of rare hereditary disorders. According to the U.S. National Library of Medicine and National Institute of Health records, around 6 million patients are suffering from PID worldwide. Increasing incidences of these diseases are projected to boost the demand for immunoglobulin therapies during the forecast period.
- Rising Healthcare Expenditure
Over the last few decades, it has been witnessed that global per capita healthcare spending has improved a lot because of the increasing rate of awareness associated with the availability of treatments and diagnostic methods for treating numerous diseases. This increasing healthcare expenditure is most likely to result in the growing demand for better diagnostic methods, which can create high growth opportunities for key market players operating in treating these conditions in the market.
Opportunities
- Increase in Elderly Population
The market is estimated to witness a heavy growth rate in the forecast period driven by the factor of an aging population. The rising demand in the market is the replication of the increasing elderly population, as people aged over 60 years often develop low immunity conditions, affecting the normal functioning. This boost the market growth.
- Rising Autoimmune Disorders
The number of people affected with autoimmune diseases is growing gradually across the world. The main cause of a number of these diseases can be traced to a lack of healthy lifestyle and dietary habits and genetics that can activate these diseases. An increase in these diseases boosts the global hypogammaglobulinemia drugs market.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel unable to perform the treatments could reduce the growth of the hypogammaglobulinemia drugs market during the forecast period.
- 免疫介导炎症疾病药物的副作用
治疗过程中产生的不良副作用阻碍了市场的增长。皮疹等副作用以及一些免疫抑制药物可能导致自身免疫反应。
本低丙种球蛋白血症药物市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关低丙种球蛋白血症药物市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
全球低丙种球蛋白血症药物市场范围
低丙种球蛋白血症药物市场根据适应症、治疗、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
指征
- 皮质类固醇
- 化疗
- 抗癫痫药物
- 其他的
治疗
- 抗生素
- 免疫球蛋白替代疗法
- 其他的
最终用户
- 医院
- 专科诊所
- 其他的
分销渠道
- 医院药房
- 零售药店
- 其他的
全球低丙种球蛋白血症药物市场区域分析/见解
对低丙种球蛋白血症药物市场进行了分析，并按上述适应症、治疗、最终用户和分销渠道提供了市场规模洞察和趋势。
低丙种球蛋白血症药物市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
北美占据市场主导地位，因为该产品的主要制造商数量众多，并且研发活动不断增加，医疗保健支出也不断增加。
由于低丙种球蛋白血症药物市场的新研究和开发的增加，预计亚太地区将占据最大的市场。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球低丙种球蛋白血症药物市场份额分析
低丙种球蛋白血症药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对低丙种球蛋白血症药物市场的关注有关
低丙种球蛋白血症药物市场的主要参与者包括：
- Biotest AG（德国）
- Octapharma Brasil Ltda（瑞士）
- Grifols, SA（西班牙）
- 中超联赛（美国）
- Kedrion SpA（意大利）
- LFB（法国）
- 武田药品工业株式会社 (日本)
- ADMA Biologics, Inc.（美国）
- 拜耳公司（德国）
- Option Care Health Inc.（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
